<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We estimated the prevalence and prognostic significance of neuroendocrine (NE) cells in a series of 208 resection specimens containing gastroesophageal junction (GEJ) <z:mp ids='MP_0009308'>adenocarcinomas</z:mp>, with 56 specimens containing Barrett's mucosa </plain></SENT>
<SENT sid="1" pm="."><plain>Immunohistochemically, chromogranin A (CGA) was positive in 49% (102/208) of GEJ <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> and in 68% (38/56) of Barrett's mucosas </plain></SENT>
<SENT sid="2" pm="."><plain>CGA in GEJ <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> correlated with pTNM stage </plain></SENT>
<SENT sid="3" pm="."><plain>CGA in Barrett correlated with pTNM stage and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> grade of the adjacent <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with CGA in Barrett had better survival than patients without CGA in Barrett, with 5-year survival percentages of 56% and 9%, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>In multi-variate analysis, CGA in Barrett was an independent prognostic factor for survival after surgery </plain></SENT>
<SENT sid="6" pm="."><plain>Therefore CGA in Barrett adjacent to GEJ <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> might be helpful in the assessment of patient outcome </plain></SENT>
</text></document>